Solid Biosciences Announces Collaboration With Mayo Clinic To Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies
Solid Biosciences Inc., which acquired UF Startup AavantiBio, has partnered with Mayo Clinic to advance an AAV gene therapy platform for next-generation treatments targeting genetic cardiomyopathies and channelopathies linked to sudden cardiac death.